Intra-Cellular: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term ‘Buy’


Olivier Le Moal

Investment Overview

The share price of Intra-Cellular Therapies (NASDAQ:ITCI) – the New York based central nervous system focused biotech – is up by 450% across a five-year period, and >50% over a 12-month period.

The company completed its initial public



Source link

Scroll to Top